• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Gastro Hep Adv . Factors associated with poor outcomes among COVID-19 patients with gastrointestinal symptoms

tetano

Editor, Senior Moderator
Gastro Hep Adv


. 2022 Aug 26.
doi: 10.1016/j.gastha.2022.08.004. Online ahead of print.
Factors associated with poor outcomes among COVID-19 patients with gastrointestinal symptoms


Nikita Patil[SUP] 1 [/SUP], Pankush Kalgotra[SUP] 2 [/SUP], Suneha Sundaram[SUP] 3 [/SUP], Stephanie Melquist[SUP] 4 5 [/SUP], Sravanthi Parasa[SUP] 6 [/SUP], Madhav Desai[SUP] 4 7 [/SUP], Prateek Sharma[SUP] 4 7 [/SUP]



Affiliations

Abstract

Background & aims: Gastrointestinal (GI) symptoms are present in 20% of patients with COVID-19. We studied the association of GI symptoms (in COVID-19 patients) with adverse outcomes and factors associated with poor outcomes in these patients.
Methods: The study cohort included 100,902 patients from the Cerner Real World Data (CRWD) COVID-19 Database of hospital encounters and emergency department (ER) visits with COVID-19 infection from December 1, 2019, to November 30, 2020. Multivariate analysis was used to study the effect of GI symptoms on adverse outcomes, and the factors associated with acute respiratory distress syndrome (ARDS), sepsis, and ventilator requirement or oxygen dependence in COVID-19 patients with GI symptoms.
Results: Patients with COVID-19 and GI symptoms were significantly more likely to have ARDS (OR 1.20, 95% CI 1.11, 1.29), sepsis (OR 1.19, 95% CI 1.14, 1.24), acute kidney injury (OR 1.30, 95% CI 1.24, 1.36), venous thromboembolism (OR 1.36, 95% CI 1.22, 1.52) or GI bleed (OR 1.62, 95% CI 1.47, 1.79); and less likely to experience cardiomyopathy (OR 0.87, 95% CI 0.77, 0.99) or death (OR 0.71, 95% CI 0.67, 0.75). Among those with GI symptoms, older age, higher Charlson comorbidity index scores, and use of proton pump inhibitors (PPI)/ H2 receptor antagonists (H2RA) were associated with higher mortality, ARDS, sepsis, and ventilator or oxygen requirement.
Conclusion: Patients with COVID-19 who have GI symptoms have overall worse in-hospital complications, but less cardiomyopathy and mortality. Older age, higher comorbidity scores, and the use of PPI and H2RA are associated with poor outcomes in these patients.

Keywords: AKI, Acute kidney injury; ARDS, acute respiratory distress syndrome; Acute respiratory distress syndrome; CCI, Charlson comorbidity index; CI, confidence interval; COVID-19, SARS-CoV-2 coronavirus infection; CRWD, Cerner real-world data; ER, Emergency Department; GERD, gastroesophageal reflux disease; GI, gastrointestinal; H2 receptor antagonist; H2RA, H2 receptor antagonist; ICD-10-CM, The International Classification of Diseases, Tenth Revision, Clinical Modification; ICD-9-CM, The International Classification of Diseases, Ninth Revision, Clinical Modification; Mortality; OR, Odds ratio; PPI, proton pump inhibitors; VTE, Venous thromboembolism; proton pump inhibitor.
 
Back
Top Bottom